Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study

Neurology

Volumn 79, Issue 16, 2012, Pages 1636-1644

  Doraiswamy, P Murali ^a   Sperling, Reisa A ^b   Coleman, R Edward ^a   Johnson, Keith A ^b   Reiman, Eric M ^c   Davis, Mat D ^d,e   Grundman, Michael ^f,g   Sabbagh, Marwan N ^h   Sadowsky, Carl H ⁱ   Fleisher, Adam S ^c,g   Carpenter, Alan ^j   Clark, Christopher M ^j   Joshi, Abhinay D ^j   Mintun, Mark A ^j   Skovronsky, Daniel M ^j   Pontecorvo, Michael J ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Theorem Clinical Research   (United States)

^f Global R and D Partners   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SUN HEALTH RESEARCH INSTITUTE   (United States)

ⁱ NOVA SOUTHEASTERN UNIVERSITY   (United States)

^j AVID RADIOPHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETAPIR F 18;

AGED; ALZHEIMER DISEASE; ALZHEIMER'S DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DEMENTIA RATING SUM OF BOXES; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN AGGREGATION; RISK ASSESSMENT;

EID: 84871195205     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182661f74     Document Type: Article

References (30)

1. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011;76:280-286.
2. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7: 270-279.
3. Weiner MW, Aisen PS, Jack CR Jr., et al. Alzheimer's Disease Neuroimaging Initiative: progress report and future plans. Alzheimer Dement 2010;6:202-211.
4. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-S2.
5. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106:6820-6285.
6. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound B. Ann Neurol 2004;55:306-319.
7. Nordberg A, Rinne JO, Kadir A, Långstrǒm B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010;6:78-87.
8. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66:1469-1475.
9. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PiB PET study. Neurology 2009;73:754-760.
10. Jack CR Jr., Wiste HJ, Vemuri P, et al, Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-toprogression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-3348.
11. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011;76:1085-1090.
12. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aand cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-192.
13. Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008;46:1688-1697.
14. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557-568.
15. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-peptide deposition identified with Pittsburgh compound B. Arch Neurol 2009;66:1476-1481.
16. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-measured by [11C]PiB. Neurology 2010;74:807-815.
17. Pontecorvo M, Mintun M. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther 2011;3:11.
18. Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009;50:1887-194.
19. Clark CM, Schneider JA, Bedell BJ, et al, AV45-A07 Study Group. Use of florbetapir-PET for imaging betaamyloid pathology. JAMA 2011;305:275-283.
20. Barthel H, Gertz HJ, Dresel S, et al, for the Florbetaben Study Group. Cerebral amyloid-PET with florbetaben (18)F in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424-435.
21. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-135.
22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group on Alzheimer's disease. Neurology 1984;34:939-944.
23. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol Epub 2011 Jul 11.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc B 1995;57:289-300.
25. Rowe CC, Ellis KA, Rimajovae M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31:1275-1283.
26. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative: The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer Dement 2010;6:221-229.
27. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011;7: 280-292.
28. Jack CR Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
29. Amyvid (florbetapir F 18 injection) [product insert]. Indianapolis: Eli Lilly & Co; April 2012.
30. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascendingdose study. Lancet Neurol 2010;9:363-372.